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EmatIron Overload in Patients Receiving Allogeneic
Hematopoietic Stem Cell Transplantation:
Quantification of Iron Burden by a Superconducting
Quantum Interference Device (SQUID) and Therapeutic
Effectiveness of Phlebotomy
Alessandro Busca,1 Michele Falda,1 Paola Manzini,2 Sergio D’Antico,2 Adriano Valfre`,2
Franco Locatelli,1 Roberto Calabrese,3 Annalisa Chiappella,1 Stefano D’Ardia,1
Filomena Longo,3 Antonio Piga3Iron overload (IO) is a known adverse prognostic factor in patients who undergo allogeneic hematopoietic
stem cell transplantation (HSCT) for thalassemia and appears to play a similar role in patients with other
hematologic disorders. The estimation of IO is based primarily on serum ferritin level; however, many con-
founding factors can result in ferritin overestimation, especially in HSCTrecipients. The aim of the present
study was to quantify IO after HSCTusing a superconducting quantum interference device (SQUID), and to
evaluate the impact of IO on hepatic function and infections. In addition, the feasibility of iron depletion was
investigated. A total of 102 consecutive allogeneic HSCTrecipients admitted to our outpatient department
between December 2005, and December 2007, were analyzed. Primary diagnosis included acute leukemia/
myelodysplastic syndrome in 61% of cases. Assessment of IO after HSCT included serum ferritin; in those
with hyperferritinemia (ferritin. 1000 ng/mL), liver iron concentration (LIC) was evaluated by SQUID mag-
netic susceptometry. Iron removal therapy was offered to patients with moderate IO (LIC 1000-2000 mg Fe/g
wet weight [ww]) or severe IO (LIC.2000 mg Fe/g ww). Fifty-seven patients had a ferritin level\1000 ng/
mL: the median time between HSCT and assessment of ferritin level was 1006 days (range, 93-5239 days),
significantly different from the median time of 183 days (range, 78-2957 days) in the 45 patients with a ferritin
level .1000 ng/mL. Out of 42 patients evaluated by SQUID, 29 had moderate to severe IO (median LIC
value, 1493 mg Fe/g ww [range, 1030-3253]). In a multivariate analysis, a significant correlation was found
between a ferritin level .1000 ng/mL and the presence of at least one abnormal liver function test (LFT)
ORo5 6.8; 95% CI5 2.2-20.6). In addition, the rate of proven/probable invasive fungal disease was signifi-
cantly higher in the patients with hyperferritinemia (13% vs 0%; P5.006). Nineteen of the 24 patients con-
sidered eligible for iron-depletion therapy underwent regular phlebotomy; 13 completed the program in
a median of 287 days (range, 92-779 days), reaching the target of a ferritin level\500 ng/mL; LIC was sig-
nificantly reduced (median, 1419 mg Fe/g ww to 625 mg Fe/g ww; P\ .001) in 8 of the 9 patients who
were revaluated by SQUID at the end of the iron-depletion program. In conclusion, the measurement of
LIC obtained by SQUID documented the presence of moderate/severe IO in 69% of the patients with
a high ferritin level. Our data showed that in HSCTrecipients, high ferritin level is an independent risk factor
for abnormal LFTs, and IO may be considered a potential risk factor for fungal infections. A phlebotomy pro-
gram may be feasible in two-thirds of the patients who might benefit from iron depletion.
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116 Biol Blood Marrow Transplant 16:115-122, 2010A. Busca et al.INTRODUCTION committee. Written informed consent was obtainedIron overload (IO) is a well-established adverse
prognostic factor in patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT) for
thalassemia [1,2], and also appears to play a similar
role in patients with other hematologic disorders
[3-5]. Some studies indicate that IO may be considered
a risk factor contributing to posttransplantation liver
toxicity, veno-occlusive disease (VOD), increased sus-
ceptibility to infection, and graft-versus-host disease
(GVHD) and may have a negative impact on survival
as well [4,6,7].
Estimation of the iron burden is based primarily on
ferritin as a surrogate marker for IO; however, many
confounding factors can cause ferritin overestimation,
particularly in HSCT recipients [8,9]. Thus, ferritin
value alone is not an ideal measure of total body iron
burden. A superconducting quantum interference de-
vice (SQUID), magnetic resonance imaging (MRI),
and liver biopsy are more appropriate means of esti-
mating liver iron content (LIC) [10-15]. On the other
hand, whether iron depletion by either phlebotomy or
chelation following allogeneic HSCT is feasible, and
which patients might benefit from these procedures,
remain unclear [13,16].
The aim of the present study was to quantify post-
transplantation IObymeans of serum ferritin, SQUID,
and quantification of transfused iron in a cohort of 102
patients who underwent allogeneic HSCT. Further
analyses included the impact of IO on hepatic function,
infectious complications, and GVHD, as well as the
feasibility and effect of an iron-depletion program.PATIENTS AND METHODS
The study started in December 2005, and patient
enrollment ended in December 2007. All patients un-
dergoing allogeneic HSCT from January 1999 who
were alive in continuous complete remission and had
a minimum follow-up of 3 months were included in
the trial and prospectively evaluated for posttransplan-
tation IO. During this time frame, a total of 311
patients underwent allogeneic HSCT. Of these, 102
consecutive patients who fulfilled the inclusion criteria
were included in the study; 136 patients who relapsed
and 67 who died of transplantation-related complica-
tions, as well as 6 patients who were lost to follow-
up, were not included in the analysis.
Underlying diseases included acute leukemia and
myelodysplastic syndrome (MDS) in two-thirds of
the patients. Table 1 summarizes demographic and
clinical characteristics of the patients. The study was
performed in accordance with the Helsinki Declara-
tion and was approved by the Local Ethics Reviewfrom all participating patients.
IOwas initially assessed using different biomarkers,
including serum iron, ferritin, and transferrin and trans-
ferrin saturation. For the purpose of this study, hyper-
ferritinemia was defined as a serum ferritin
level. 1000 ng/mL [17-19]. Serial liver function tests
(LFTs) were performed after transplantation at the
time of iron status assessment, including aspartate ami-
notransferase (AST; reference range, 8-30 UI/L),
alanine aminotransferase (ALT; reference range,
5-35UI/L), gammaglutamyl transpeptidase (GGT; ref-
erence range, 8-35 UI/L), and alkaline phosphatase
(ALP; reference range, 42-141 UI/L). Liver dysfunc-
tion was based on abnormally elevated LFT values on
2ormoreoccasions.All patientswereevaluated forhep-
atitis B virus (HBV) and hepatitis C virus (HCV) status.
In patients with a serum ferritin level.1000 ng/mL
in complete remission of their underlying disease,
a quantitativemeasurement of LIC by SQUIDwas per-
formed.
Data on the number of blood units transfused be-
fore SQUID evaluation were obtained from the blood
bank of San Giovanni Battista Hospital. The iron con-
tent of the blood units collected in the blood bank
between January 2005 and December 2008 (a total of
197,894 units) was calculated by multiplying the mea-
sured hemoglobin content by the volume of the unit by
3.4. The estimated mean iron content of our blood
bags was 213 mg. The total mg of iron transfused
per kg of recipient body weight was calculated, assum-
ing that each unit of packed red blood cells (PRBCs)
contained 213 mg of iron.
Medical charts were reviewed for GVHD status
and the occurrence of bacteremias and invasive fungal
infections between the day of transplantation and
SQUID assessment.
A phlebotomy program was proposed to all
patients with a ferritin value. 1000 ng/mL and IO
confirmed by SQUID (LIC .1000 mg Fe/g ww).
With each phlebotomy, approximately 350-500 mL
of whole blood was removed, depending on the
patient’s body weight. A complete blood count was
analyzed before each phlebotomy, and the procedure
was not performed in patients with a hemoglobin lev-
el\11 g/dL. Phlebotomies were repeated every 1-2
weeks until a serum ferritin level\500 ng/mL was
measured. Iron removed in the single phlebotomy
was calculated by multiplying the volume of the phle-
botomy by hemoglobin concentration by 3.4. The
total amount of iron removed was then calculated.Statistical Analysis
The data were analyzed using SPSS version 16 for
Windows (SPSS Inc, Chicago, IL). Normality was as-
sessed by the Shapiro-Wilk test and exploratory data
Table 1. Patient and Transplantation Characteristics
Number of patients 102
Median age, years (range) 47 (21-67)
Underlying disease
Acute myeloid leukemia 38 (37%)
Myelodysplastic syndrome 17 (17%)
Lymphomas 26 (25%)
Chronic myelogenous leukemia 6 (6%)
Myeloma 4 (4%)
Acute lymphoblastic leukemia 7 (7%)
Aplastic anemia 2 (2%)
Myelofibrosis 1 (1%)
Renal cell carcinoma 1 (1%)
Year of transplantation
1999-2000 15
2001-2002 13
2003-2004 18
2005-2006 40
2007 16
Type of transplant
Matched sibling donor 66 (65%
Matched unrelated donor 32 (31%)
Partially matched related donor 4 (4%)
Graft source
Bone marrow 17 (17%)
Peripheral blood 84 (82%)
Cord blood 1 (1%)
Intensity of conditioning regimen
Myeloablative 58 (57%)
Reduced-intensity 44 (43%)
Conditioning regimen
TBI 1200 cGy + Cy 23 (22%)
TBI 200 cGy + fludarabine 24 (23%)
TBI 200 cGy 2 (2%)
Thiotepa-Cy 38 (37%)
Busulfan-containing regimen* 6 (6%)
Other 9 (10%)
TBI indicates total body irradiation; Cy, cyclophosphamide.
*Four patients received busulfan 16 mg/kg by oral administration; 2 pa-
tients received busulfan 12.8 mg/kg i.v.
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continuous variables and frequencies (%) for categori-
cal variables. Differences between groups were assessed
using theMann-Whitney test, whereas associations be-
tween categorical variables were evaluated using
Fisher’s exact test. Univariate and multivariate logistic
regression models were used to analyze the effects of
some relevant variables (ie, hepatitis, chronic GVHD
[cGVHD], disease status, timing of ferritin assessment,
and hyperferritinemia) on liver dysfunction. Time of
ferritin assessment was included in themodels as a cate-
gorical variable using tertiles. The correlation between
ferritin andLICwith the amount of iron transfusedwas
assessed by Spearman’s correlation coefficient. All sta-
tistical tests were 2-sided and significant for P\ .05.RESULTS
Iron Overload
The median serum ferritin level was 837 ng/mL
(range, 18-11,110 ng/mL). Twenty-eight patients had
a ferritin valuewithin thenormal range (reference range,
25-340 ng/mL), and 74 patients (72%) had an above-
normal ferritin value. Overall, 45 of the 102 patients(44%) had a serum ferritin level. 1000 ng/mL. IO
assessment was performed at a median time of 578
days after HSCT (range, 78-5293 days). In the cohort
of patients with hyperferritinemia, the median time
fromHSCT to ferritin assessment was 183 days (range,
78-2957 days), significantly shorter than the median
time of 1006 days (range, 93-5239 days) in the 57 pa-
tients with a ferritin level below the threshold of 1000
ng/mL(P\.0001) (Table2).Hyperferritinemiawasde-
tected in 59% (32/54) of the patients with acute leuke-
mia or MDS, compared with 27% (13/48) of those
with a different diagnoss (P5 .002).
A pre-HSCT serum ferritin value was available for
63 patients. Thirty-three of these patients had a ferritin
level below the threshold of 1000 ng/mL (median, 529
ng/mL; range, 15-991 ng/mL); 10 of these patients
exhibited hyperferritinemia post-HSCT. Thirty of
the patients had a ferritin level$ 1000 ng/mL
(median, 1963 ng/mL, range, 1083-18,290 ng/mL);
25 of these maintained a high ferritin level post-
HSCT, while 5 exhibited a spontaneous decrease in
ferritin level.
LIC (mg Fe/g ww) was evaluated by SQUID in 42
of the 45 patients with a ferritin level. 1000 ng/mL.
IO was not assessed by SQUID in 2 patients who
developed disease recurrence and in 1 patient who
died shortly after ferritin assessment. Quantification
of LIC by SQUID was obtained at a median of 49
days (range, 3-338 days) after the assessment of serum
ferritin. Overall, the median LIC value was 1298 mg
Fe/g ww (range, 250-3253 mg Fe/g ww), correspond-
ing to 7.6 mg Fe/g dry weight (range, 1.5-19 mg Fe/
g dw). Twenty patients (48%) had moderate IO (LIC
1000-2000 mg Fe/g ww), and 9 (21%) had severe IO
(LIC. 2000 mg Fe/g ww). Five patients (12%) had
normal a LIC value (\ 400 mg Fe/g ww) despite
a high serum ferritin level; 4 of these patients had
GVHD involving the liver (n5 2), skin (n5 1), or
oral mucosa and eye (n5 1), and 1 patient had severe
CNS infection. The patients with an LIC .1000 mg/
g ww received a median of 32 PRBCs (range, 7-101)
and a median of 116 mg/kg of iron (range, 12-316) be-
fore SQUID evaluation. The biochemical parameters
and transfusion data are summarized in Table 2.
We found a statistically significant correlation
between serum ferritin level and the amount of iron
transfused, defined as mg of iron transfused per kg of
recipient body weight (r5 0.709; P\ .001). The cor-
relation between amount of iron transfused and LIC as
measured by SQUID was statistically significant only
in male recipients (r5 0.510; P5 .018).Effect of Iron Overload on HSCTOutcome
At the time of IO assessment, LFT values were
above the upper limit of normal in 69 of the 102
patients. Thirty-one of the 57 patients (54%) with
Table 2. Iron Burden Measurements and Liver Function Tests after Transplantation
Patients with Hyperferritinemia (Ferritin$ 1000 ng/mL) Patients with Ferritin < 1000 ng/mL P
Number of patients 45 57
Serum iron, mg/dL 136 (33-378) 82 (12-348 <.001*
Transferrin saturation, % 56 (13-110) 31 (5-101) <.001*
Ferritin, ng/mL 1609 (1027-11110) 346 (6-974) <.001*
Time to ferritin assessment, days 183 (78-2957) 1006 (93-5239) <.001*
LIC, ngFe/g ww) 1311 (298-2476) -
LIC, ng/g dw) 7.6 (1.7-16.4) -
Total iron transfused, mg/kg 107.9 (12.1-316.3) 32.2 (4.7-209.8) <.001*
Patients with LFT above UNL, n (%)
AST 25 (55%) 19 (33%) .028†
ALT 32 (71%) 19 (33%) <.001†
GGT 31 (69%) 21 (37%) .001†
ALP 7 (15%) 7 (12%) .773†
AST, U/L 35 (14-291) 26 (15-288) .091*
ALT, U/L 50 (9-904) 28 (6-594) .001*
GGT, U/L 72 (8-1262) 28 (8-302) <.001*
ALP, U/L 92 (34-546) 83 (44-324) .345*
AST indicates aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gammaglutamyl transpeptidase; ALP, alkaline phosphatase.
Data are reported as median (range) unless specified otherwise.
*Mann-Whitney test.
†Fisher’s exact test.
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abnormal LFT value, compared with 38 of the 45 pa-
tients (84%) with post-HSCT hyperferritinemia
(P5 .001). Thirty-five percent of the patients with
a serum ferritin level\1000 ng/mL (20/57) and 71%
of those with hyperferritinemia (32/45) had 2 or
more abnormal LFT values (P \ .001). Median
GGT and ALT values were significantly higher in
the patients with hyperferritinemia, whereas there
was only a trend toward higher AST values in the pa-
tients with hyperferritinemia (Table 2).
In both univariate and multivariate analyses, a sig-
nificant association was found between ferritin lev-
el. 1000 ng/mL and liver dysfunction, defined by
the presence of at least 1 abnormal LFT value on 2
or more occasions. This association is statistically sig-
nificant even when the varying times of ferritin assess-
ment are included in the multivariate model (Table 3).
Three patients with a ferritin level\1000 ng/mL
and 4 patients with hyperferritinemia were HBV-
positive. Two patients with a ferritin level\1000
ng/mL and 1 patient with hyperferritinemia were
HCV-positive.
Severe acute GVHD (aGVHD) grade II-IV oc-
curred in 24 patients. Eight of these patients (33%)
had a ferritin level. 1000 ng/mL, compared with 37
of 78 patients (47%) with aGVHD grade 0-I
(P5 .326). No significant correlation was found
between hyperferritinemia and the presence of
cGVHD (P5 .685).
No patient included in the study presented with
clinical signs of VOD. Nine 9 patients who died of
a transplantation-related complication (n5 7) or dis-
ease recurrence (n5 2) during the first 3 months
post-HSCT had evidence of VOD. These patients
were not included in the analysis.Information on the occurrence of bacteremia was
available for 94 patients. Overall, 12 patients had a pos-
itive blood culture, including 7 patients (16%) with
hyperferritinemia and 5 patients (10%) with a serum
ferritin level\1000 ng/mL (P5 .455). Isolates were
Staphilococcus coagulase negative (n5 5), Staphilococcus
aureus (n5 2),Corynebacterium jeikeium (n5 1),Escher-
ichia coli (n5 2), Pseudomonas aeruginosa (n5 1), and
Stenotropomonas maltophilia (n5 1). One patient with
hyperferritinemia, but a normal LIC developed
a bloodstream infection.
Invasive fungal disease (IFD) developed in 6
patients (13%) with hyperferritinemia but in none of
the patients with a serum ferritin level\1000 ng/mL
(P5 .006). Five of these cases were defined as probable
pulmonary aspergillosis according to established crite-
ria [20]; 1 patient had invasive candidiasis of the esoph-
agus. The median time between HSCT and the
diagnosis of IFD was 12 days (range, 0-110 days),
and the median time from diagnosis of IFD to the
assessment of serologic ferritin level was 14 months
(range, 2-30 months). One patient with hyperferritine-
mia but a normal LIC developed IFD. In 5 of the 6
patients with IFD, a serum ferritin measurement was
available before the diagnosis of IFD was made; in 4
of these cases, the ferritin level was. 1000 ng/mL
and in the remaining case the level was 991 ng/mL.
Overall, 16 patients died. Of the 9 patients who
died of transplantation-related complications, 6 had
hyperferritinemia; of the 7 who died of recurrence of
the underlying disease, 6 had hyperferritinemia.Effect of Phlebotomy
Of the 29 patients with LIC. 1000 mg Fe/g ww, 3
were considered ineligible for an iron-depletion
Table 3. Impact of Hyperferritinemia on Liver Function
Variable Patients with liver dysfunction* Univariate OR (95% CI) Multivariate OR (95% CI)
Hepatitis
No (n5 92) 49 (53%) 1 -
Yes (n5 10) 8 (80%) 3.5 (0.7-17.4) -
Chronic GVHD
Absent (n5 60) 30 (50%) 1 -
Limited (n5 28) 17 (61%) 1.5 (0.6-3.8) -
Extensive (n5 14) 10 (71%) 2.5 (0.7-8.9) -
Disease status
Early (n5 56) 34 (61%) 1 -
Advanced (n5 46) 23 (50%) 0.6 (0.3-1.4) -
Timing of ferritin assessment (days after HSCT)
< 192 (n5 34) 17 (50%) 1 1
193-1006 (n5 34) 19 (56%) 1.3 (0.5-3.3) 2.7 (0.8-8.7)
> 1007 (n5 34) 21 (62%) 1.6 (0.6-4.2) 5.4 (1.5-20.1)
Hyperferritinemia
< 1000 ng/mL (n5 57) 31 (54%) 1 1
> 1000 ng/mL (n5 45) 38 (84%) 3.1 (1.3-7.0) 6.8 (2.2-20.6)
GVHD indicates graft-versus-host-disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gammaglutamyl transpeptidase;
ALP, alkaline phosphatase.
*Patients with at least one abnormal liver function test (AST, ALT, GGT, or ALP).
Min-Max
25%-75%
Median value
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0
1000
2000
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Figure 1. The impact of phlebotomy on serum ferritin level and LIC.
The median ferritin level was 1459 ng/mL (range, 1084-4376 ng/mL) be-
fore phlebotomy (columnA), compared to 373 ng/mL (range, 59-535 ng/
mL) after completion of the program (column B) (P\.001). The median
LIC was 1419 mg Fe/g ww (range, 1030-2384 mg Fe/g ww) before phle-
botomy (column C) and 625 mg Fe/g ww (range, 250-1703 mg Fe/g ww)
after completion of the program (column D) (P\.001).
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ing malignancy (n5 2) or poor general condition
(n5 1). Two patients who exhibited a spontaneous
normalization of ferritin level were not considered
for iron depletion; at the time of ferritin assessment,
1 of these patients hadmildly elevated LFT values con-
sistent with hepatic GVHD, and the other had con-
comitant cytomegalovirus (CMV) and urinary tract
infections (UTIs).
Five patients (17%) were not eligible for a phlebot-
omy program. Three of these patients were treated
with deferasirox, 1 patient was treated with desferriox-
amine because of a low hemoglobin level, and 1 patient
received no treatment because of his poor general con-
dition. Deferasirox was admistered at a dose of 10 mg/
kg/day in all patients but 1, who received 20 mg/kg.
Nineteen patients (65%) with LIC. 1000 mmg
Fe/g ww were treated by regular phlebotomy. The
venesections were initiated between day 1210 and
day 13488 post-HSCT (median, day 1757).
Recombinant erythropoietin was used in 2 cases to fa-
cilitate planned phlebotomy. For 1 patient, the pro-
gram is still ongoing, whereas 13 patients completed
the program, reaching the target goal of ferritin lev-
el\500 ng/mL after a median of 16.5 phlebotomies
(range, 8-38) and 2392 mg of iron removed (range,
1160-5510 mg). The median duration of the phlebot-
omy program was 287 days (range, 92-779 days).
The effect of phlebotomy on IO is illustrated in
Figure 1. One of the 9 patients evaluated by SQUID
showed no remarkable reduction in LIC despite serum
ferritin normalization. Interestingly, patients who
completed the phlebotomy program exhibited signifi-
cantly improved LFT values. Eight of the 12 patients
with abnormalLFTvalues before the initiationof phle-
botomy had normalization of at least 1 test at the end of
the program. The median AST value was 57 U/L(range, 46-86 U/L) before phlebotomy and 27 U/L
(range, 21-39 U/L) at the end of treatment
(P5 .027). The median ALT value was 98U/L (range,
50-140 U/L) before phlebotomy and 28 U/L (range,
20-51U/L) at the end of treatment (P5 .007).Theme-
dian GGT value was 212 U/L (range, 58-1262 U/L)
before phlebotomy and 51 U/L (range, 23-237 U/L)
at the end of treatment (P5 .017). Five patients discon-
tinued the phlebotomy program. Two of these patients
were switched to deferasirox because of the presence of
hypotension (1 case) and progressive anemia (1 case); 2
patientswho relapsed and1patientwhodiedofGVHD
received no additional iron chelation.
Overall, 5 patients received deferasirox for
a median duration of 270 days (range, 37-425 days).
One patient discontinued deferasirox because of the
occurrence of transplantation-related complications
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tient did so because of an increase in serum creatinine
level concomitant with the higher dose of deferasirox
(20 mg/kg). Two patients completed the treatment,
reaching ferritin levels of 356 ng/mL and 885 ng/mL,
respectively. One patient is currently undergoing the
treatment. Overall, deferasirox was well tolerated,
with transient mild gastrointestinal disturbances re-
ported in 2 cases and cutaneous rash reorted in 1
case. No cases of drug-related cytopenia were noted.DISCUSSION
IO is a relevant but often underestimated compli-
cation in HSCT recipients, primarily resulting from
the paucity of tools available for a reliable diagnosis
of iron burden. Given these considerations, 2 major
factors are of particular clinical interest: the frequent
misleading diagnoses, including GVHD and drug-
related toxicity, and the need to extensively evaluate
and validate all therapeutic approaches [10,16].
In the present study, we assessed the prevalence of
IO in 102 HSCT recipients at varying time intervals
from transplantation, using serum ferritin level to indi-
rectly estimate IO and SQUID to directly measure
LIC. Overall, 44% of our patients exhibited evidence
of IO based on serum ferritin level; this relatively
high prevalence of IO is in agreement with the 58%
reported by Rose et al [11] and the 32% reported by
Majhail et al [13]. The quantification of LIC by
SQUID confirmed the presence of moderate to severe
iron burden in two-thirds of the patients with hyper-
ferritinemia. To the best of our knowledge, the assess-
ment of iron burden by SQUID in HSCT recipients
has been reported in only 1 previous study [14]. In
the present study, 5 patients had normal LIC despite
a high ferritin level, and 2 patients experienced sponta-
neous normalization of ferritin level. We can hypoth-
esize that the significant inflammatory status
associated with the comorbidities present in these
patients at the time of ferritin assessment (ie, GVHD
in 5 cases and severe infection in 2 cases) might be
responsible for the misleading serum ferritin values.
A significant correlation between LIC and the
amount of iron transfused was seen only in male recip-
ients, possibly because of the variable physiological
blood loss in females. Alternatively, the study’s small
sample size may account for this finding. In addition,
it is well known that transfusions are not the only cause
of IO in patients with hematologic malignancies and
those undergoing HSCT. Other possible causes of
IO include ineffective erythropoiesis leading to de-
creased iron utilization, increased intestinal absorption
of iron due to mucositis and GVHD, and abnormal
hepcidin regulation [10,16,21]. Recently, it also has
been hypothesized that alloreactive T cell-dependentsignals may induce dysregulation of intestinal iron ab-
sorption [22]. Considering that liver biopsy with esti-
mation of LIC is the reference method for measuring
hepatic iron stores [23], but is an invasive procedure
and may not be feasible in thrombocytopenic patients,
we can hypothesize that body iron stores in patients
after HSCT are optimally assessed through a compre-
hensive study of iron burden, including the evaluation
of serum ferritin level, amount of iron transfused, and
LIC by SQUID or MRI.
The median time interval from HSCT to ferritin
measurement was significantly shorter in the patients
with hyperferritinemia comparedwith those with a fer-
ritin level\1000 ng/mL (183 days vs 1006 days), sug-
gesting that a physiological decrease in ferritin level
may occur post-HSCT, as has been reported in previ-
ous studies [24,25]. Alternatively, the high ferritin level
might reflect the proinflammatory condition usually
observed during the first 6 months post-HSCT, in
which GVHD and infectious complications play a cru-
cial role. In this respect, it is noteworthy that 9 of 13
patients with hyperferritinemia, but LIC\1000 mg
Fe/g ww underwent the biochemical assessment within
6months after HSCT, suggesting that, at least in these
patients, the ferritin value might not represent a true
condition of IO.
Liver dysfunction is a very common complication
of allogeneic HSCT, occurring in 57%-80% of pa-
tients [8,9,15,26]. GVHD, drug toxicity, VOD, and
infections are the most common factors involved in
the etiology of liver dysfunction in allogeneic HSCT
recipients, although more recently IO has emerged
as an important cause of abnormal LFT values
[9,15,16,26], particularly in the intermediate/late post-
transplantation period (. 30 days post-HSCT). Our
results support the latter observation; 38 of 69 patients
with abnormal LFT values had a high serum ferritin
level, and multivariate analysis confirmed a significant
correlation between hyperferritinemia and liver dys-
function. It is noteworthy that this correlation reached
statistical significance, even when the varying time to
ferritin estimation was included in the statistical
model, thereby minimizing the potential effects of
other confounding factors, such as regimen-related
toxicity, GVHD, and infections, which usually are
more relevant during the first 6 months post-HSCT.
ALT andGGTwere the LFT values that most fre-
quently exceeded the upper limit of normal in the pa-
tients with hyperferritinemia, and they reached
a significantly higher median peak level in the patients
with high ferritin levels. To the best of our knowledge,
these findings have not previously reported in the liter-
ature. Given our findings, transplantation clinicians
should be aware that elevated ALT and particularly
GGT might reflect the damage of iron burden, al-
though unfortunately these parameters are not specific
for, but rather are merely suggestive, of hepatic IO.
Biol Blood Marrow Transplant 16:115-122, 2010 121Iron Overload in Allogeneic TransplantationOuranalysis has confirmed that IO is a potential risk
factor for IFD, as has been reported previously [27,28],
although this finding should be confirmed in larger pro-
spective clinical trials. In this respect, it would be of in-
terest to evaluate whether iron depletion is able to
restore the capacity of the host to combat infection.
Alternatively, the possibility that iron starvation might
slow the growth of fungal hyphae is intriguing [29,30].
Phlebotomy is the treatment of choice for patients
who develop IO after HSCT. Based on European
Group for Blood andMarrow Transplantation recom-
mendations, long-term HSCT survivors with IO
documented by LIC. 7 mg Fe/g dw should be treated
with phlebotomy and chelation therapy [31]. Several
studies have documented the feasibility and efficacy
of a phlebotomy program in HSCT recipients. Butt
et al [25] reported that ferritin levels fell more rapidly
in autograft recipients who underwent venesection
than in those who did not undergo venesection. Rose
et al [11] reported the results of phlebotomy in 29
patients with abnormal LIC estimated byMRI after al-
logeneic HSCT. Ferritin level normalized in 86% of
the evaluable patients, and 62% of the patients had
normalized hepatic biology after phlebotomy. Tomas
et al [9] described 26 patients with chronic liver dys-
function after allogeneic HSCT who were included
in a iron-depletion program. Of these patients, 23
underwent venesection at a median of 539 days after
HSCT, and improved LFT values were documented
in 21 of them. Our findings confirm that iron depletion
by phlebotomy significantly reduces both ferritin level
and LIC as assessed by SQUID. In addition, phlebot-
omy helped ameliorate abnormal LFT values, as dem-
onstrated by the fact that 67% of the patients exhibited
normalized LFT values after completing the program.
Nevertheless, a consistent proportion of HSCT recip-
ients may not be eligible for phlebotomy because of
coexisting anemia. These patients may benefit from
treatment with an iron-chelating agent; however, few
studies have analyzed the feasibility and the effective-
ness of these agents following HSCT [30,32,33]. In
our study, 5 patients were treated with the oral chelator
deferasirox, and 2 of these patients discontinued
therapy because of drug-related side effects, including
gastrointestinal disturbance and renal insufficiency.
Unfortunately, given the small number of cases in-
cluded in the present analysis, a meaningful conclusion
regarding the efficacy of deferasirox in the setting of
post-HSCT IO cannot be drawn.
In conclusion, themeasurement of LIC by SQUID
documented the presence of moderate to severe IO in
69% of our HSCT recipients with high ferritin levels.
Estimation of iron status by measuring serum ferritin
level seems to be more precise at least 6 months after
HSCT, avoiding the possible interference of inflamma-
tory factors on ferritin measurement. Our data show
that high ferritin level is an independent risk factor forthe occurrence of abnormal LFT values, and that IO
may be considered a potential risk factor for fungal
infection. A phlebotomy program was feasible in two-
thirds of the patients who might benefit from iron
depletion and effectively normalized LFT values in
67% of the patients.Whether alternative strategies, in-
cluding oral iron-chelating agents, may be useful in this
setting merits further investigation. In addition, larger
prospective clinical trials are needed to verify the appli-
cability of phlebotomy even in early stages post-HSCT.ACKNOWLEDGMENTS
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